INOVIO Pharmaceuticals, Inc. — Q3 2013 Form 10-Q
Business context and reporting period. The filing covers the quarter and nine months ended September 30, 2013. Inovio develops DNA vaccines and immune therapies, with candidates in research and clinical development; it reported no product sales and no approved human products. The interim financial statements are unaudited.
Financial performance and position
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Revenue | $9.49 million | $0.85 million | $11.73 million | $2.98 million |
| Operating expenses | $8.72 million | $7.15 million | $23.27 million | $20.25 million |
| Income (loss) from operations | $0.77 million | $(6.29) million | $(11.54) million | $(17.27) million |
| Net loss attributable to Inovio | $(30.88) million | $(6.62) million | $(50.57) million | $(19.01) million |
| Net loss per share | $(0.16) | $(0.05) | $(0.29) | $(0.14) |
- Revenue and margins: Revenue increased substantially, primarily from $8.4 million of Roche license revenue recognized in Q3. Q3 operating income was positive, but nine-month operations remained loss-making. Gross margin is not separately presented.
- Cash flow: Nine-month operating cash use was $16.3 million, investing cash use was $4.5 million, and financing provided $48.2 million. Cash and cash equivalents rose to $33.1 million from $5.6 million at year-end 2012.
- Liquidity: Cash plus short-term investments totaled $46.2 million; working capital was $37.4 million. Management estimated these funds would cover planned working capital needs into Q1 2016, while stating that additional outside financing would be needed thereafter.
- Balance sheet and debt: Total assets were $88.0 million and total liabilities were $25.8 million. The filing does not report conventional borrowings; a material current liability of $14.1 million related to stock warrants was recorded.
Material changes and unusual items
- Roche entered a collaboration and license agreement for INO-5150 (prostate cancer) and INO-1800 (hepatitis B), with an exclusive worldwide license and an option on additional vaccines. The agreement provides for up to $412.5 million in development, regulatory, and commercial event-based payments, plus tiered royalties. The $10 million upfront payment was received after quarter-end; $8.4 million was recognized as Q3 license revenue and the balance was deferred. No milestones were achieved in the reported periods.
- The nine-month net loss included a $39.6 million noncash expense from revaluing common stock warrant liabilities, mainly reflecting the increase in Inovio’s share price. This substantially widened the reported net loss despite improved operating results.
- Equity financing and exercises of warrants and options generated significant cash but increased share count. The company raised approximately $14.0 million net in a March offering, received $15.1 million net through its at-the-market program, and received $19.1 million from warrant and option exercises during the first nine months.
- Research and development expense rose to $15.0 million for nine months, while general and administrative expense rose to $9.3 million. Costs included a $1.1 million sublicense fee associated with Roche and increased rent and consulting expenses.
Outlook, commentary, and risks
- Management expected substantial operating losses to continue and said Inovio may never achieve positive cash flow or profitability. Future operations depend on further financing, collaborations, grants, and progress in development.
- Key development setbacks included a ChronTech hepatitis C study that did not show statistically significant efficacy versus the drug regimen alone, after which Inovio ceased that collaboration. A University of Southampton leukemia-vaccine Phase II study was on hold because of sponsor funding interruption; the filing reported no safety concerns.
- The company described clinical, regulatory, manufacturing, intellectual-property, funding, and collaborator-performance risks. Its candidates require further testing and regulatory approval, and prior trial results may not predict later outcomes.
- A ten-year San Diego office and research facility lease was entered into; monthly base rent is scheduled to range from zero to $82,945, plus operating expenses and a management fee.
- Disclosure controls and procedures were assessed as effective at September 30, 2013. No legal proceedings were reported as applicable.
Important facts for investors to verify
- Whether the Roche collaboration produces the anticipated milestones, development support, and eventual royalties; distinguish contingent potential payments from contracted or received cash.
- Cash consumption and financing needs against management’s stated runway into Q1 2016, including the effect of continued R&D spending and warrant-related liabilities.
- Clinical progress and funding status of key programs, particularly the hepatitis B, prostate cancer, HCV, and WT1 leukemia programs.
- Future warrant revaluations and exercises, which can materially affect reported earnings and shareholder dilution.
- Whether grants, government contracts, and collaborations remain funded and replaceable, given the company’s lack of product revenue and history of losses.